Respiratory Disease

At Bioxydyn we lead the field in using oxygen as a contrast agent for lung imaging to provide quantitative imaging-based regional measurements of gas delivery, ventilation and perfusion.  We are also leaders in the use of conventional contrast agents to assess lung perfusion and MRI-based measurements of lung mechanics. 

Our methods and software tools provide a significant benefit over existing pulmonary tests, such as spirometry, due to their ability to quantify lung function regionally.  Our technologies set a new standard for functional lung imaging in the management of respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD), cystic fibrosis and pulmonary hypertension.

Standard lung function tests such as spirometry are not sufficiently sensitive or precise and provide no information on regional lung function. To help fill this gap, imaging techniques are becoming increasingly important in managing lung disease. X-ray CT is a useful diagnostic method but radiation exposure and the inability of CT to characterise lung function limit its use. SPECT and scintigraphy also require ionising radiation and suffer from poor resolution, while other MRI based techniques are too complex and costly to play a practical role in clinics. Bioxydyn’s patented oxygen-enhanced MRI (OE-MRI) methods can be applied easily in Radiology Departments. They allow easily-implemented, repeatable, non-ionising, non-invasive quantificaiton of the impact of regional lung disease. 

Bioxydyn’s pioneering OE-MRI imaging tools, embedded in the Pulmolux platform, use oxygen as an MR imaging agent, which is delivered to the patient whiel breathing freely in the scanner. OE-MRI allows us to monitor the delivery of oxygen to the patient's lung exchange tissues. The acquired signals are subject to proprietary modelling techniques, embedded in Bioxydyn’s software tools, to generate quantitative imaging biomarkers of regional lung perfusion and ventilation. Bioxydyn also has substantial experience of the use of conventional contrast agents for characterisation of lung vascular status, and of the use of MR image time series for the quantification of lung tissue density and mechanical properties. The Pulmolux suite of tools has been developed to allow respiratory researchers to identify alterations in lung ventilation, vasculature, perfusion and structure and the effect of therapy on a regional basis.